MedMira Inc. Stock Analysis MIR.V

MedMira, Inc. is a biotechnology company, which engages in the development and commercialization of rapid diagnostics and technology platforms. The firm's tests provide hospitals, labs, clinics and individuals with an instant disease diagnosis, such as human immunodeficiency virus (HIV), syphilis, hepatitis, and SARS-CoV-2, in three steps. The firm is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. Its research is focused on specific areas of the broader diagnostics market, namely the rapid, point-of-care, and in vitro sectors. Its tests are sold globally under the REVEAL, REVEALCOVID-19, Multiplo and Miriad brands. Based on its patented Rapid Vertical Flow Technology, the Company's rapid HIV test has regulatory approvals in Canada, the United States, China and the European Union. Its manufacturing facilities are located in Halifax, Nova Scotia, Canada. The company provides access to its RVF Technology for researchers, developers, and biotech companies on a license basis.